Galapagos NV has partnered with Blood Centers of America to open multiple manufacturing sites throughout the U.S. for its cell-based medicines, aiming to differentiate itself in the CAR-T cancer therapy market. The partnership will support the company in advancing its CAR-T therapies for different cancers into pivotal studies and potentially launching them upon approval. This collaboration addresses the challenges of limited access to existing CAR-T therapies due to the complex manufacturing process involving the removal, engineering, and infusion of immune cells. The deal is expected to expand treatment capacity and improve patient access to these potent cancer treatments.
Source link
Galapagos to make CAR-T therapies at blood centers across U.S.
